



Pfizer – Independent Grants for Learning & Change (IGLC) and Lilly Grant Office Call for Grant Applications (CGA)

Advances in the Future of Chronic Pain Management

I. Background

Pfizer and Lilly are collaborating to provide grant support for continuing professional education in the area of pain. We are committed to supporting innnovative, independent medical education for healthcare professionals. Grants via this collaboration will be funded by Pfizer, but reviewed and approved by both companies. Further information about their collaboration is available on the Pfizer grant website.

The mission of Pfizer Independent Grants for Learning & Change (IGLC) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. "Independent" means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

Through this CGA we encourage organizations to submit grant requests that, if funded, will support education in a specific disease state, therapeutic area, or broader area of educational need. Educational activities should not be focused on products specific to Pfizer and/or Lilly.

Grant applications should be submitted through Pfizer. When a CGA is issued, it is posted on the IGLC website in the <u>Grants Process section</u> and is sent via e-mail to all registered users in our grants system. Some CGAs may also be posted on the websites of other relevant organizations.

II. Eligiplility	
Geographic Scope:	☑ United States Only
Applicant Eligibility Criteria:	The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to
	Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions/organizations/associations, are encouraged. All partners must have a relevant role, and the requesting organization must have a leadership role.

II. Eligibility

III. Requirements	
Date CGA Issued:	September 4, 2018
Clinical Area:	Pain

Specific Area of Interest for this CGA:	This CGA seeks to support educational initiatives and tools to help health care practitioners broaden their understanding and use of available resources to appropriately recognize and treat chronic pain.
	It is our intent to support continuing professional education for Pain Specialists and PCPs (including Internal Medicine, PM&R, NP, PA and other relevant extended staff) that focus on:
	 Advancing current understanding of pain pathophysiology, pain pathway (including the role of various mediators) acute/chronic pain, epidemiology of chronic pain, impact (functional, physical, economic etc.), burden (societal, familial, employer, payer etc.). Describing current challenges (including proper assessment and available tools) involved in the appropriate care of patients who suffer from chronic pain.
	 Discussing current standards of care and available guidelines in chronic pain; with focus on Osteoarthritis (OA) and Chronic Low Back Pain (CLBP). Exploring emerging treatments in chronic pain.
	Program types: While it is expected that programing targeted at addressing knowledge gaps will involve live sessions such as grand rounds, efforts should be made to encourage interaction and provide opportunities to extend learning opportunities beyond the live setting such as web-based education. Requests with components that include live sessions at annual conferences will be considered. Other delivery formats (see below) and educational approaches will also be considered.
	 CME/CE – Enduring Materials: case studies, microsite, toolkits use of smart phone apps and other point-of-care learning methods. Venues of interest: Major/Relevant meetings for Pain Specialists, Primary Care, PM&R, NP, PA and other relevant staff.
	The successful applicant will propose projects that actively engage the learner, employ innovative learning technologies, provide opportunities for learner exchange and include measurement techniques (needs assessment and outcomes data that allows for meaningful assessment of program impact).
	More information on principles of learning and behavior change for health professionals can be found at <u>www.pfizer.com/files/HealthProfessionalsLearningandBehaviorChange</u> <u>AFewPrinciples.pdf</u> .
	3

Expected Approximate	The total available budget related to this CGA is approximately
Monetary Range of	\$1,000,000. The typical grant maximum under this CGA will be up to
Grant Applications:	\$250,000. However, larger proposals up to \$1,000,000 will be
	considered for funding if they include multiple activities such as several
	live events, enduring activities, and supportive materials and tools.
	The grant amount Pfizer and Lilly will be prepared to fund will depend
	upon the evaluation of the proposal and costs involved and will be
	stated clearly in the approval notification.
Key Dates:	CGA release date: September 4, 2018
	Grant application due date: September 30, 2018
	Please note the deadline is midnight Eastern Time (New York, GMT -5).
	······································
	Anticipated Grant Award Notification Date: December 1, 2018
	Grants distributed following execution of fully signed Letter of
	Agreement (LOA). Note projects may not start until after LOA is fully
	executed.
	Period of Performance: Projects to begin January 2019. Maximum
	project length is 2 years.
How to Submit:	
How to Submit:	Please go to the specific <u>application log-in page</u> and sign in. First-time
	users should click "REGISTER NOW".
	Select the following Educational Areas CCA. Advances in the Future of
	Select the following Educational Area: CGA- Advances in the Future of
	Chronic Pain Management
	Requirements for submission:
	Complete all required sections of the online application and upload the
	completed CGA template (see Appendix). If you encounter any
	technical difficulties with the grant management system, please click
	the "Need Support?" link at the bottom of the page.
	the Need Support? This at the bottom of the page.
	IMPORTANT. Do advised applications submitted through the surgers
	IMPORTANT: Be advised applications submitted through the wrong
	application type and/or submitted after the due date will not be
	reviewed by the committee.
_	If you have questions regarding this CGA, please direct them in writing
Questions:	to Robert Kristofco at Robert.Kristofco@pfizer.com with the subject line
	"CGA- Pain Management."
Mechanism by which	All applicants will be notified via email by the dates noted above.
Applicants will be	
Notified:	Applicants may be asked for additional clarification or to make a

IV. Terms and Conditions

Please take note every Call for Grant Applications (CGA) released by Pfizer Independent Grants for Learning & Change (IGLC) is governed by specific terms and conditions. These terms and conditions can be reviewed here: http://www.pfizer.com/files/PfizerIGLC_CGA_TermsandConditions_2017Nov.pdf

Appendix: CGA Grant Submission Template

Grant Applications should be single-spaced using <u>Calibri 12-point font</u> and <u>1-inch margins</u>. Note there is a <u>15-page limit</u> exclusive of references. Please include the following:

- A. Title
- B. Organizational Detail: Describe the attributes of the institutions/organizations that will support and facilitate the execution of the project, the leadership of the proposed project, and the specific role of each partner in the proposed project.
- C. Goal: Briefly state the overall goal of the project.
- D. Objectives: List the objectives you plan to meet with your project, in terms of learning and expected outcomes.
- E. Assessment of Need: Include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.
- F. Target Learner Audience: Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.
- G. Project Design and Methods: Describe the planned project, the educational approach, and the way the planned methods address the established need.
- H. Innovation: Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.
- I. Outcomes Evaluation: In terms of the metrics used for the needs assessment, describe how you will determine if the gap was addressed for the target group. Identify the sources of data you anticipate using to make the determination. Describe how you expect to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms of your target audience. Describe how you will determine if the target audience was fully engaged in the project.
- J. Dissemination Plan: Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.
- K. Timeline
- L. Additional Information: If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize it in within the page limitations.
- M. References (outside the 15-page limit)
 - There is no designated format for references
- N. Budget (See template available in application)
 - While estimating your budget please keep the following items in mind:
 - Grants awarded by IGLC cannot be used to purchase therapeutic agents (prescription or non-prescription).
 - Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for projects.
 - A separate Excel file should be uploaded. This does not count toward the page limit.
 - An example of the budget template can be found here: <u>http://cybergrants.com/pfizer/docs/KnowledgeGapBudgetTemplate2015.xls</u>
 - At the conclusion of your program, a reconciliation of expenses is required using the original budget file submitted.

Grant Applications should be single-spaced using <u>Calibri 12-point font</u> and <u>1-inch margins</u>. There is a <u>15-page limit</u> exclusive of references. If extensive, references may be included on 1-2 additional pages.